Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 in Relapsed or Refractory Mature Lymphoid Neoplasms
NCT03603951Phase 1Active, not recruiting
- Sponsor
- Hengrui
- Start
- Aug 2018
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zeprumetostat in mature lymphoid neoplasm and peripheral T-cell lymphoma (PTCL), sponsored by Hengrui. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 6 months, Recommended phase 2 dose at 30 days and 1 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
zeprumetostat
03
Conditions
mature lymphoid neoplasmperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03603951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603951.